Available Brands
Did you find this information helpful?
Author Details

Written By
P. Thirumal Reddy
B. Pharm

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 13 Oct 2026 | 11:42 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
LETERMOVIR
Last updated on 13 Oct 2026 | 11:42 AM (IST)
LETERMOVIR
Molecule Overview
Letermovir is an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in certain transplant recipients. It belongs to a new class of medicines that block CMV in a different way from older antivirals, avoiding some of their common side effects. It is a prescription-only medicine.
Medical Classification
Therapeutic Class: Antiviral medicine for cytomegalovirus (CMV) prophylaxis.
Pharmacological Class: CMV DNA terminase complex inhibitor (non-nucleoside).
Drug Family: 3,4-dihydro-quinazoline antivirals.
ATC Classification: J05AX18 (Letermovir).
Conditions Treated
Approved: Prophylaxis of CMV disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT); and prophylaxis of CMV disease in adult and pediatric kidney transplant recipients (12 years and older, weighing at least 40 kg) at high risk (donor CMV-seropositive/recipient CMV-seronegative).
Commonly used for: Transplant patients at risk of CMV reactivation or infection, as a preventive measure started around the time of transplant.
Off-label use (only under medical guidance): Sometimes explored for CMV prevention in other solid organ transplant settings under specialist guidance.
Available Strengths & Dosage Forms
● Oral tablets: 240 mg and 480 mg.
● Oral pellets: for pediatric patients unable to swallow tablets, in various lower strengths.
● Injection (intravenous infusion): available for patients unable to take oral medication.
How the Molecule Works
Letermovir blocks a part of the CMV virus called the terminase complex, which the virus needs to correctly package its genetic material into new viral particles during replication. By inhibiting this specific step, letermovir prevents the virus from producing new infectious copies of itself, without affecting the same pathways that older CMV antivirals (like valganciclovir) act on — which is part of why it tends to cause less bone marrow suppression.
Dosage & Administration
Standard dose (HSCT prophylaxis): 480 mg orally or intravenously once daily, reduced to 240 mg once daily if co-administered with cyclosporine; typically started after transplant and continued through 100 days post-transplant.
Condition-wise dose (kidney transplant prophylaxis): 480 mg once daily (orally or intravenously), initiated between Day 0 and Day 7 post-transplant and continued through Day 200 post-transplant.
Route: Oral (tablet or pellets), with or without food, or intravenous infusion when oral dosing isn't possible.
Cyclosporine adjustment: If cyclosporine is started after letermovir, the next letermovir dose is reduced to 240 mg/day; if cyclosporine is stopped, the next letermovir dose is increased back to 480 mg/day.
Missed dose: Take as soon as remembered on the same day; don't double up — resume the regular schedule.
Overdose: Not established beyond recommended dosing; managed with supportive care and monitoring.
Side Effects
Common: Nausea, diarrhoea, vomiting, swelling in the limbs (peripheral edema), cough, headache, and fatigue.
Serious: Elevated liver enzymes, and, in rare cases, significant allergic reactions.
Emergency symptoms: Yellowing of the skin/eyes, severe abdominal pain, or signs of a serious allergic reaction (swelling of the face/throat, difficulty breathing).
Recovery advice: Common side effects like nausea are usually mild and manageable; unlike older CMV antivirals, letermovir does not typically cause significant bone marrow suppression, which is one of its key advantages.
Warnings & Precautions
Pregnancy: Used only if clearly needed, under medical guidance, as data are limited.
Breastfeeding: Discussed with the treating doctor given limited safety data.
Liver disease: Used with caution; not recommended with the IV formulation in severe hepatic impairment combined with moderate/severe renal impairment, due to a specific excipient concern.
Kidney disease: The IV formulation contains an excipient (hydroxypropyl betadex) that can accumulate in reduced kidney function; serum creatinine is monitored closely in patients receiving IV letermovir with significant renal impairment.
Elderly: Used with routine monitoring; no specific age-based dose adjustment required.
Children: Approved for kidney transplant CMV prophylaxis in patients 12 years and older weighing at least 40 kg, with weight-based dosing for lower weight bands using pellets or lower-dose IV.
Drug Interactions
● Pimozide and ergot alkaloids: contraindicated in combination with letermovir due to the risk of serious toxicity.
● Cyclosporine: significantly increases letermovir levels, requiring the letermovir dose to be reduced to 240 mg/day.
● Certain statins (e.g., simvastatin, atorvastatin): letermovir can increase their levels, requiring dose adjustment or closer monitoring.
● CYP3A4/2C9 substrates and other transporter-affected drugs: numerous interactions are possible given letermovir's effect on drug-metabolising enzymes and transporters — a full medication review is recommended before starting.
Monitoring Requirements
● Liver function tests periodically.
● Serum creatinine monitoring in patients receiving IV letermovir with reduced kidney function.
● CMV viral load monitoring as part of standard post-transplant surveillance.
● Cyclosporine level monitoring when used together, given the two-way interaction.
Alternative Molecules
Valganciclovir, Ganciclovir (older CMV antivirals with a different mechanism and more bone marrow suppression risk); Foscarnet, Cidofovir (used for resistant CMV or specific clinical situations).
Combination Therapies
In kidney transplant CMV prophylaxis studies, letermovir has been used alongside acyclovir (for other viral prophylaxis needs); dose adjustment is specifically required when combined with cyclosporine, one of the standard immunosuppressants used post-transplant.
● Cytomegalovirus (CMV) Prophylaxis
● Transplant Supportive Care
● Antiviral Therapies
FAQs
Q1.
It's used to prevent CMV infection and disease in adult stem cell transplant recipients who are CMV-seropositive, and in high-risk adult (and certain pediatric) kidney transplant recipients.
Q2.
It works through a different mechanism (blocking the CMV terminase complex) and generally causes less bone marrow suppression, making it a preferred option for CMV prevention in many transplant settings.
Q3.
Cyclosporine significantly raises letermovir levels in the blood, so the letermovir dose is halved (to 240 mg) when the two are taken together to avoid excess exposure.
Q4.
Yes, the oral tablet can be taken with or without food.
Q5.
This depends on the transplant type — commonly through 100 days post-transplant for stem cell transplant recipients, or through 200 days post-transplant for high-risk kidney transplant recipients.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






